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Background: Numerous studies have reported the economic burden of childhood diarrhea in low- and middle-
income countries (LMICs). Yet, empirical data on the cost of diarrheal illness is sparse, particularly in LMICs. In this
study we review the existing literature on the cost of childhood diarrhea in LMICs and generate comparable
estimates of cost of diarrhea across 137 LMICs.
Methods: The systematic literature review included all articles reporting cost estimates of diarrhea illness and
treatment from LMICs published between January 2006 and July 2018. To generate country-specific costs, we used
service delivery unit costs from the World Health Organization’s Choosing Interventions that are Cost-Effective
(WHO–CHOICE database). Non-medical costs were calculated using the ratio between direct medical and direct
non-medical costs, derived from the literature review. Indirect costs (lost wages to caregivers) were calculated by
multiplying the average GDP per capita per day by the average number of days lost to illness identified from the
literature. All cost estimates are reported in 2015 USD. We also generated estimates using the IHME’s service
delivery unit costs to explore input sensitivity on modelled cost estimates.
Results: We identified 25 articles with 64 data points on either direct or indirect cost of diarrhoeal illness in
children aged < 5 years in 20 LMICs. Of the 64 data points, 17 were on the cost of outpatient care, 28 were on the
cost of inpatient care, and 19 were unspecified. The average cost of illness was US$36.56 (median $15.73; range
$4.30 – $145.47) per outpatient episode and $159.90 (median $85.85; range $41.01 – $538.33) per inpatient episode.
Direct medical costs accounted for 79% (83% for inpatient and 74% for outpatient) of the total direct costs. Our
modelled estimates, across all 137 countries, averaged (weighted) $52.16 (median $47.56; range $8.81 – $201.91)
per outpatient episode and $216.36 (median $177.20; range $23.77 –$1225.36) per inpatient episode. In the 12
countries with primary data, there was reasonable agreement between our modelled estimates and the reported
data (Pearson’s correlation coefficient = .75).
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Conclusion: Our modelled estimates generally correspond to estimates observed in the literature, with a few
exceptions. These estimates can serve as useful inputs for planning and prioritizing appropriate health interventions
for childhood diarrheal diseases in LMICs in the absence of empirical data.
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Diarrheal deaths in children have declined by more than
55% globally [1–3] since 2000. Despite impressive gains,
diarrhea remains one of the leading causes of global dis-
ease burden, accounting for approximately 1.1 billion ep-
isodes, 450,000 deaths, and 40 million disability-adjusted
life-years (DALYs), among children under five in 2016.
Countries in South Asia and sub-Saharan Africa account
for almost 90% of global diarrheal deaths in children and
a significant share of the total disease burden [3].
Childhood diarrhea imposes economic costs on the
health system and families. These costs are especially
poignant in resource-limited settings. Often referred
to as disease of poverty, repeated bouts of diarrhea
can lead to malnutrition, stunting and delayed brain
growth later in life costing individuals and societies
substantial economic burden [4–6]. Proven solutions
to cost -effectively address diarrhea are available, in-
cluding interventions like oral rehydration therapy [7],
micronutrient supplementation [8], rotavirus vaccines
[9, 10], as well as general improvements in water and
sanitation [11]. Increasing access to existing solutions
will be important to prevent and further lower diar-
rheal disease burden [12].
Cost has been shown to hinder households’ access to
diarrhea treatment in many countries [13]. Diarrheal dis-
ease largely contributes to the vicious cycle of ill health
and poverty due to economic burden [14, 15]. Although
studies have reported costs of treating diarrhea in a
number of countries (e.g., Malawi [16], Colombia [17],
Bolivia [18], Bangladesh [19]), diarrhea treatment costs
are not universally known across low- and middle-
income countries. A previous systematic review [20] in-
cluded only studies focusing on Latin America and the
Caribbean. As data on cost of illness is a useful input for
prioritizing, selecting, and scaling up appropriate health
interventions, country-specific estimates of the costs of
diarrhea illness are important for policy and advocacy
purposes.
The objective of this analysis was to provide more
comprehensive diarrhea illness cost estimates in low-and
middle-income countries. To achieve this objective, we
first conducted a systematic review of empirical studies
on cost of diarrhea illness and treatment among children
under age five in low-and middle-income countries. We
then generated modelled country-specific estimates ofdiarrhea treatment cost for 137 low-and middle-income
countries. We also compared our modelled estimates to
the empirical literature, when available, as a consistency
check in our efforts to extend diarrhea cost estimates be-
yond the countries that have empirical estimates avail-
able. The cost estimates generated are intended to be
useful inputs to estimating the costs of managing diar-
rheal diseases both globally and, particularly, in settings
where data are lacking.Methods
Review of published studies
We conducted a systematic literature search to identify
all published peer-reviewed studies reporting cost of
diarrhea and rotavirus illness and treatment among chil-
dren under 5 years. The search was limited to include
studies from low-and middle-income countries pub-
lished in English language between January 2006 and
July 2018. Studies from high-income countries, and
those that did not involve primary data collection and
reported only modelled estimates of cost data were
excluded.
Literature searches were conducted in the following
electronic databases: Embase Ovid Excerpta (PUBMED/
MEDLINE), Cochrane Library, Web of Science core
collections, EconLit, and Google Scholar using the key
search terms “Direct healthcare cost”, “Indirect health-
care cost”, “Burden of illness”, “Diarrhea”, “Rotavirus”,
“Low-income countries” and “Middle-income coun-
tries”. A full overview of the electronic search strategies
used for different databases is provided in Additional
file 1. Studies included for final review had to report
the empirical costs of diarrhea illness. Data on direct
medical costs, direct non-medical costs, and indirect
costs of treating a diarrhea episode at any level of
health care facilities, as well as the cost per episode of
diarrhea, either for inpatient or outpatient care setting,
were collected as primary study outcomes. The multiple
database searches were stored in EndNote X7
(Thompson Reuters, CA, USA). A full review protocol
was developed at the beginning of this study and is available
from PROSPERO (PROSPERO 2018: CRD42019119816).
We used the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines as a guide
in identifying relevant studies for the review. A PRISMA
Baral et al. BMC Public Health          (2020) 20:619 Page 3 of 13flow chart illustrating the selection process is shown in
Fig. 1.
Three authors (SAA, RB, JN) independently screened
all identified relevant articles based on the title and ab-
stract. Any disagreements in study selection were re-
solved through discussion among authors (RB, CP, JN,
SAA) after a review of the full-text of potentially relevant
studies. All relevant studies thus selected were retrieved
and reviewed for full text. Data extraction was per-
formed independently by two authors (SAA, RB). Ex-
tracted data were discussed and discrepancies were
resolved before final compilation of extracted data into a
pre-developed Excel template. Extracted data from each
study were aggregated and/or re-categorized where
needed to obtain harmonized and comparable measures
of primary outcomes; i.e., direct medical, direct non-
medical, indirect, and total cost per inpatient and out-
patient episode treated.
Cost estimates extracted from the included studies
were converted and presented in 2015 USD units. For
currency conversion to standard 2015 USD units, cost
estimates in the source literature were first converted toFig. 1 PRISMA flow diagram of the literature searchlocal currency units (LCU) for the given year, then in-
flated to 2015 LCU using country-specific annual infla-
tion rates, and then converted to 2015 USD [21]. GDP
deflator values were used to adjust for inflation, and offi-
cial exchanges rates were used to convert LCU to USD.
Both data series were obtained from the World Bank’s
World Development Indicators database [22].Comparison of cost estimates
To assess the within-country consistency of reported es-
timates, we examined estimates for countries with mul-
tiple costing studies and a comparable metric. We used
direct medical costs for either inpatient or outpatient
visits as the comparable metric, as they were a measur-
able and commonly reported component of total costs.Modelling diarrhea cost of illness
To model diarrhea cost of illness in 137 low-and
middle-income countries, we first estimated the direct
medical costs, direct non-medical costs, and indirect
costs. We then aggregated these three cost components
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episodes of diarrhea (see Fig. 2).
Direct medical cost estimates are based on the WHO-
CHOICE database, which provides country-specific ser-
vice delivery unit cost estimates [23], as well as costs of
commodities typically used in diarrhea treatment. Using
inflation-adjusted 2010 WHO-CHOICE unit cost esti-
mates received from WHO, we converted them to 2015
USD using methods described above. For inpatient costs,
we used country-specific bed day costs estimates at sec-
ondary level hospitals, assuming an intermediate level of
care, and a four-day length of stay as used elsewhere
[10]. Based on the recommendation from disease ex-
perts, we assumed that ORS would be given to any diar-
rhea case after each stool. We assume that one inpatient
diarrhea case would receive six packs of oral rehydration
solution (ORS) treatment per day in the facility as well
as two intravenous (IV) solutions during their stay (as-
sumptions based on expert opinion). Per MSH’s Inter-
national Medical Products Price Guide, we value each
packet of ORS at $0.29 and IV solution at $0.55 [24].
Outpatient direct medical costs were estimated in a
similar manner. The country-specific cost per outpatient
visit was also taken from WHO-CHOICE using a pri-
mary care hospital as the treatment setting. OutpatientFig. 2 Methods for calculating comparable estimates of cost of diarrhea illncases were assumed to receive six ORS packets per day
for 2 days.
Direct non-medical costs build on direct medical cost
calculations as well as empirical cost estimates from the
literature. Most studies included in our systematic re-
view only reported either the total direct cost and/or dir-
ect medical costs but not direct non-medical costs. We
therefore calculated the direct medical cost share as a
proportion of total direct costs in the papers in which
these values were presented. We then averaged the dir-
ect medical cost share across studies and multiplied our
modelled country-specific estimate of direct medical
costs by the reciprocal of the average direct medical cost
share, which resulted in total direct cost estimates for
each country. After obtaining total direct costs, we cal-
culated direct non-medical costs by multiplying total dir-
ect cost estimates with the direct non-medical cost
share. Separate calculations were made for outpatient
and inpatient illness episodes using respective cost
shares from the literature.
Indirect costs estimates were sparse and inconsistently
reported in the literature. To calculate indirect cost of
illness, we used income lost to providing care for the
sick children. We utilize 2015 World Bank’s gross do-
mestic product (GDP) per capita estimates for eachess and treatment
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the value of a lost caretaker day [25]. We assume in-
patient caretakers lose 8.4 productive days and out-
patient caretakers lose 4.3 productive days as based on
the literature [26]. We then multiplied the number of
days lost to providing care for sick children by the GDP
per capita per day to estimate indirect costs.
As a sensitivity test to the primary inputs used for
modelling country specific cost of illness, the WHO-
CHOICE unit cost estimates, we also generated esti-
mates using a more recently published IHME service de-
livery unit cost estimates [27] and compared the results
generated using the two sources.
Results
Search results from review of published studies
We identified 3167 studies through our database search.
Upon excluding duplicate records, we screened 3051
studies for relevance of which only 62 were eligible for
full text review. Twenty-five of the studies met the inclu-
sion criteria and were included in the final review and
data extraction (Fig. 1).
Characteristics of studies included
Studies identified for quantitative analysis in the system-
atic review (N = 25) represented six low- income coun-
tries (LIC) [16, 28–32], nine lower-middle-income
countries (LMIC) [18, 19, 30, 33–44], and five upper-
middle-income countries (UMIC) [13, 17, 45–47], as
classified by the World Bank’s income groups in 2018
[25]. While most studies reported using societal perspec-
tive (22/25, 88%) in measuring cost [13, 17–19, 29–32,
34–37, 39, 41–49], we observed a wide variation in use
of term societal perspective across those studies. One
study each reported using payer [33] and provider [28]
perspectives. One study [40] did not explicitly report the
perspective used. Seven studies exclusively focused on
measuring inpatient costs [13, 31, 34, 35, 38, 40, 46].
The remaining studies [18/25] included costs of both in-
patient and outpatient care [16–19, 28–30, 32, 33, 36,
37, 39, 41–45, 47] although seven of those studies did
not explicitly distinguish between costs incurred for ei-
ther outpatient or inpatient care (see Table 1). There
were 64 unique data points on either direct or indirect
cost of diarrheal illness in children. Of these, 17 data
points were on the cost of outpatient care, 28 on in-
patient care, and the remaining 19 were not specific to
outpatient or inpatient care. We generated and reported
separate estimates from those studies.
Cost of diarrhea illness in children
Table 2 summarizes cost estimates derived from the em-
pirical literature in 2015 USD. The number of data
points from the literature used to inform the estimates isrepresented by N. The mean (unweighted) cost of illness
per outpatient episode of diarrhea in children across
low- and middle-income countries was $36.56 (median
$15.73; range $4.30 – $145.47). For inpatient care, the
average cost per episode was approximately $159.90
(median $85.85; range $41.01 – $538.33). The average
total direct cost and average indirect cost for outpatient
care were roughly equal, whereas the median values of
total direct cost was twice the median value of the indir-
ect cost. For inpatient care, the average total direct cost
was roughly 3 times the average indirect cost, but the
difference was roughly four-fold for the median values.
Based on studies that included but did not distinguish
between outpatient or inpatient cost in reporting, the
average cost of diarrhea care was about $80.50 (median
$7.28; range $2.62 – $416.72).
The observed variation in cost estimates was large
across different health care settings in which care was
sought. Data points stratified by facility types were too
sparse to generate any conclusive evidence. Nevertheless,
for outpatient, the total direct cost of illness reported av-
eraged at $3.70, $33.79, and $31.86 in primary, second-
ary, and tertiary level health care settings, respectively.
For inpatient care, the total direct costs averaged at
$30.70, $144.54, and $154.89 in primary, secondary, and
tertiary level hospital, respectively (see Additional file 2).Comparison of cost estimates
We assessed the intra-country consistency of estimates
for countries with multiple costing studies using direct
cost estimates, as they were the only indicator reported
consistently across studies. We were only able to make
within-country comparisons in a few countries. Multiple
studies from Bangladesh, Bolivia, and India reported dir-
ect medical costs for inpatient care.
For Bangladesh, the reported estimates of total direct
cost across (not distinguished by Inpatient or Outpatient)
three studies were $1.70 [29], $3.49 [43], and $22.69
[36]. The higher estimates were for a tertiary-level hos-
pital, whereas the lower estimates were from a rural set-
ting covering costs of primary care.
In Bolivia, the two publications from the same group
of authors [18, 44], which use the same data source but
with separate sub-group analyses reveal variations in dir-
ect costs across private versus public facilities and across
urban and rural areas. Both direct medical and non-
medical costs for outpatient care in rural settings were
much higher than for inpatient care. Based on their ana-
lysis, higher variation was observed in direct medical
outpatient care compared to inpatient care; direct med-
ical inpatient costs were relatively consistent across set-
tings, with the higher estimate being only 24% higher
than the lower estimate. However, the higher direct
Table 1 Characteristics of studies included in systematic review
Reference Country (ies) Income
group (s)
Currency,
year
Disease
focus
Costing
perspective
Sensitivity
analysis
Study focus
[Inpatient (IP) / Outpatient
(OP)/ Both]
Ruhago et al., 2015 [28] Tanzania LIC 2012, USD Diarrhea Provider Yes Both
Rheingans et al., 2012 [B]
[29]
India; Bangladesh;
Pakistan
LIC 2011, USD Diarrhea Societal No Both but does not distinguish
OP/IP
Ngabo et al., 2016 [31] Rwanda LIC 2014, USD Diarrhea Societal No IP
Memirie et al., 2017 [32] Ethiopia LIC 2013, USD Diarrhea Societal No Both
Hendrix et al., 2017 [16] Malawi LIC 2014, USD Diarrhea Societal No Both
Rheingans et al., 2012 [A]
[30]
Gambia; Kenya;
Mali
LMIC; LIC 2011, USD Diarrhea Societal No Both but does not distinguish
OP/IP
Wilopo et al., 2009 [33] Indonesia LMIC 2007, USD Rota Payer Yes Both
Sowmyanarayanan et al.,
2012 [34]
India LMIC 2009, INR Rota Societal No IP
Soltani et al., 2015 [35] Tunisia LMIC 2015, TND Rota Societal Yes IP
Sarker et al., 2018 [36] Bangladesh LMIC 2014, USD Diarrhea Societal Yes Both
Riewpaiboon et al., 2016
[37]
Vietnam LMIC 2014, USD Rota Societal Yes Both but does not distinguish
OP/IP
Osano et al., 2011 [38] Kenya LMIC 2008, KNH Rota Societal No IP
Mendelsohn et al., 2008
[39]
India LMIC 2006, USD Diarrhea Societal No Both
Mathew et al., 2016 [40] India LMIC 2014, INR Rota NR No IP
Jacob et al., 2016 [41] India LMIC 2014, INR Rota Societal No Both
Halder et al., 2017 [19] Bangladesh LMIC 2007, USD Diarrhea Societal No Both
Flem et al., 2009 [42] Kyrgyzstan LMIC 2008, USD Rota Societal Yes Both but OP is not used as it
is modeled
Das et al., 2015 [43] Bangladesh LMIC 2011, USD Rota Societal No Both but does not distinguish
OP/IP
Burke et al.,2014 [44] Bolivia LMIC 2011, USD Diarrhea Societal No Both
Burke et al.,2013 [18] Bolivia LMIC 2011, USD Diarrhea Societal No Both
Zhang et al., 2015 [45] China UMIC 2013, USD Rota Societal No Both
Phavichitr et al., 2013 [46] Thailand UMIC 2011, THB Diarrhea Societal No IP
Latipov et al., 2011 [13] Kazakhstan UMIC 2009, USD Rota Societal Yes IP
Alvis-Guzman et al., 2013
[17]
Colombia UMIC 2010, USD Diarrhea Societal No Both but does not distinguish
OP/IP
Alkoshi et al., 2015 [47] Libya UMIC 2013, USD Rota Societal No Both but does not distinguish
OP/IP
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times the lower outpatient cost estimate.
In India, different facility types appear to play a role in
cost differences. The total direct cost for outpatient care
in India ranged from $2.86 [39] in a primary care setting
to $21.27 [41] in a tertiary care setting. For inpatient
care, the total direct cost estimates range from $17.09
[39] in a primary hospital to $197.92 [41] in a tertiary
hospital.
Modelled estimates of cost of illness for diarrhea
To inform modelling, we used the cost structure as ob-
served from the literature along with other informationas outlined in Fig. 2. Of the 25 studies examined in the
diarrhea cost of illness literature review, 18 studies [13,
16, 18, 29–34, 36, 38, 39, 41–45, 47] reported both direct
medical and direct non-medical costs for either inpatient
or outpatient care. Using this data, we calculated direct
medical cost share as a proportion of total direct costs.
Across all studies, on average, direct medical costs
accounted for 79% of the total direct cost of treatment.
Segregating by type of care, the average direct medical
cost share was about 83% (median 85%) for inpatient
and 74% (median 75%) for outpatient care. Due to
sparseness of data in the literature by country income
group or geographic categories, we applied an average
Table 2 Summary of diarrhea cost of illness estimates from literature review (in 2015 USD)
Direct medical cost Direct non-medical cost Total
direct cost
Indirect cost Total cost
per episode
Outpatient
N 9 8 10 7 6
Mean 12.54 4.77 15.52 14.02 36.56
Median 6.64 2.98 7.23 3.48 15.73
Min 0.92 0.47 1.42 1.66 4.30
Max 58.23 18.87 77.10 68.37 145.47
Inpatient
N 15 13 16 12 11
Mean 117.58 16.99 116.79 39.19 159.90
Median 64.27 14.21 73.66 19.23 85.85
Min 24.24 1.18 29.99 2.47 41.01
Max 341.27 39.75 359.34 178.99 538.33
Unspecified In/out-patient
N 10 9 10 9 9
Mean 39.55 11.33 56.97 17.14 80.05
Median 2.84 0.72 3.37 3.58 7.28
Min 1.22 0.24 1.70 0.91 2.62
Max 299.58 91.13 390.72 74.94 416.72
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the literature across all countries to inform model esti-
mates. A summary of the modelled estimates of costs of
diarrhea illness by country income group is presented in
Table 3.
Based on our modelled estimates, the weighted average
total cost per episode of inpatient diarrhea across all
countries was $216.36. For inpatient cases, the average
cost per episode for LICs, LMICs, and UMIC was esti-
mated at $44.23, $116.59, and $491.10, respectively.
Similarly, the weighted average cost per outpatient epi-
sode was estimated to be approximately $52.16. For out-
patient cases, the weighted average cost for LICs,
LMICs, and UMICs was $13.94, $32.58, and $108.84, re-
spectively. The weighted average direct medical cost per
inpatient visit ranged was $112.41 (range $24.40 to
$259.70), while the weighted average direct medical cost
per outpatient visit was $8.03 (range $4.73 to $13.22).
The highest total cost per hospitalization was for UMICs
at $1225.36. Cross country variations in modelled esti-
mates of direct medical cost are shown in Fig. 3.
Country-specific modelled estimates of cost of illness are
provided in Additional file 3.
As a sensitivity check to the cost estimates generated
using the WHO-CHOICE service delivery unit costs, we
additionally evaluated the cost of diarrhea for both in-
patient and outpatient care using the unit cost estimatesfrom the IHME [27]. In general, the unit cost estimates
from the IHME were higher than that for the unit costs
estimate from the WHO-CHOICE. The correlation coef-
ficient between the cross-country unit cost estimates
from the two sources were positive and moderate (Pear-
son’s correlation 0.41 for inpatient unit cost and 0.63 for
outpatient unit costs). Across all countries, on average,
the cost per bed day from IHME are roughly 6 times
higher and the cost per visit were about 3 times higher
compared to the WHO-CHOICE unit costs.
In comparing the two sets of modelled average esti-
mates with the average estimate from the literature, we
find that the average cost per episode estimates were
more closely aligned with the literature when using the
WHO-CHOICE unit costs. The average difference in
average cost per episode between the literature estimate
and that derived using WHO-CHOICE unit cost was
about 35% (population weighted) to 63% (unweighted)
for inpatients; whereas the same using the unit costs
from the IHME were in the order of 357% (population
weighted) to 223% (unweighted). The differences in case
of outpatient cost per episode is much less pronounced
(see Table 4).
Comparison of modelled and literature estimates
We compared the estimates to check consistency across
modelled and empirical estimates. Figure 4 presents a
Table 3 Estimated cost of diarrhea illness in children by income group (in 2015 USD)
Inpatient Outpatient
Total Direct medical Direct non-medical Indirect Total Direct medical Direct non-medical Indirect
All countries (N = 137)
Mean 260.60 144.83 29.84 85.94 56.41 9.23 3.19 43.99
Weighted mean 216.36 112.41 23.16 80.79 52.16 8.03 2.77 41.36
Maximum 1225.36 740.48 152.57 332.31 201.91 25.61 8.83 170.11
Minimum 23.77 8.18 1.69 6.38 8.81 3.49 1.20 3.26
Median 177.20 88.87 18.31 69.39 47.56 7.83 2.70 35.52
SD 243.20 146.77 30.24 71.56 42.64 4.96 1.71 36.63
Low income countries (N = 34)
Mean 45.75 25.67 5.29 14.79 14.02 4.80 1.65 7.57
Weighted mean 44.23 24.40 5.03 14.80 13.94 4.73 1.63 7.58
Maximum 157.71 103.93 21.41 32.36 29.09 9.31 3.21 16.57
Minimum 36.60 8.18 1.69 24.56 18.38 3.49 1.20 12.57
Median 44.02 24.23 4.99 14.52 13.36 4.74 1.63 7.43
SD 22.15 15.06 3.10 4.95 3.51 0.88 0.30 2.53
Lower-middle income countries (N = 47)
Mean 143.09 74.15 15.28 53.66 36.88 7.00 2.41 27.47
Weighted mean 116.59 57.33 11.81 47.45 32.58 6.17 2.13 24.29
Maximum 312.31 205.22 42.28 97.10 63.86 13.43 4.63 49.71
Minimum 36.60 8.18 1.69 24.56 18.38 3.49 1.20 12.57
Median 134.77 68.55 14.12 48.67 35.94 6.76 2.33 24.92
SD 66.70 42.19 8.69 21.81 12.75 1.91 0.66 11.16
Upper-middle income countries (N = 56)
Mean 489.67 276.49 56.97 156.22 98.54 13.81 4.76 79.97
Weighted mean 491.10 259.70 53.51 177.89 108.84 13.22 4.56 91.06
Maximum 1225.36 740.48 152.57 332.31 201.91 25.61 8.83 170.11
Minimum 189.45 62.75 12.93 75.83 51.95 5.66 1.95 38.82
Median 452.14 250.05 51.52 144.59 93.59 13.06 4.50 74.01
SD 220.39 144.63 29.80 56.82 33.45 4.42 1.53 29.08
N represents the number of countries in each income category. The weighted mean is the mean value weighted by the country population under 5 years old (for
year 2018) in each income group
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the two sources. In each figure, the bars represent mod-
elled estimates using the WHO-CHOICE service deliv-
ery inputs and the circles represent empirical estimates.
The figures show that, apart from a few observations
such as the cost of inpatient care in Bolivia or Kenya (a)
and the cost of outpatient care in China (b) the other
estimates show general consistency between modelled
and empirical estimates. In the 12 countries with pri-
mary data, there was reasonable agreement between
our modelled estimates of direct inpatient care and
the reported data (Pearson correlation coefficient >
.75). In general, the modeled estimates are similar to
the literature estimates in more than half of the
comparisons.Similar figures that compare cost estimates from 3
sources: a. empirical estimates from the literature; b.
modelled estimates using the WHO-CHOICE service
delivery unit costs as inputs; and c. modelled estimates
using the IHME service delivery unit costs as inputs, are
included in the Additional file 6.
Discussion
We undertook a systematic review of cost of diarrhea ill-
ness among children in low-and middle-income coun-
tries. Twenty-five studies from 20 countries were
included in the analysis. We found that the average costs
of outpatient and inpatient diarrhea care per episode
were approximately $40 and $160, respectively; the
range of estimates, however, varies widely between
Fig. 3 Modelled estimates of direct medical cost for inpatient and outpatient care
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patient and inpatient care and did not report costs sep-
arately; estimates based on these studies alone suggest
the average cost of illness per episode, to be about $80.
We found considerable variation in cost estimates re-
ported in the literature. This variation can be attributed
to the methodological differences across studies, particu-
larly to variation in the perspective undertaken by stud-
ies and cost categorization. While most of the studiesTable 4 Comparison of average estimates from literature and that m
Source Inputs
Literature Not applicable
Modelled using WHO-CHOICE unit cost Population unweighted average
Population weighted average
Modelled using IHME unit cost Population unweighted average
Population weighted averageincluded in the systematic review reported costs from
societal perspective, reflecting burden to households, a
few studies reported costs from hospital or payer per-
spective. Further, there was considerable heterogeneity
in estimates in the literature based on settings from
which costing data were gathered and the health facil-
ities in which care for diarrhea was sought. We also find
a lack of standardized reporting of the cost items, a fea-
ture common across costing studies [50], adding to theodeled using unit cost inputs from different sources
Average cost per episode % difference in cost per episode
IP OP IP OP
159.90 36.56
260.60 56.41 −63% −54%
216.36 52.16 −35% −43%
730.33 64.73 −357% −77%
516.76 58.63 −223% −60%
Fig. 4 Comparison of modelled and empirical estimates of direct medical costs across countries
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vary within and between countries based on the capabil-
ities, and resources available for treatment in those set-
tings leading to some heterogeneity in reported costs
[50]. Nevertheless, the range in estimates are consistent
with findings reported in some earlier reviews [20].
Using the ratio of direct medical to total direct costs
for inpatient and outpatient care from the literature, we
modelled the cost of diarrhea care across 137 low- and
middle-income countries. Our model estimates an
weighted average cost of approximately $216 (median
$177) and $52 (median $47) per episode of diarrhea
among children in inpatient and outpatient settings,
respectively, across all 137 countries with a considerable
range in average cost estimates across country income
groups.
On average, across all countries, our modelled
weighted average outpatient cost per episode was 43%
higher than the average estimate from the literature. The
weighted average inpatient cost per episode from the
model was roughly 35% higher than that derived from
the literature. Although there are notable discrepancies
between the modelled and empirical estimates, there was
a reasonable agreement between modelled estimates and
the reported data (Pearson’s correlation coefficient > .75).
However, it should be noted that the two sets of esti-
mates are not directly comparable for various reasons.
The empirical estimates are derived from only a handful
of countries representing limited geography and
heterogeneous health care settings, as well as varying
severity of illness. The modelled estimates, on the other
hand, assume a representative primary healthcare setting
for outpatient care and a secondary hospital for inpatient
care.
We found considerable differences in cost estimates
when using the service delivery unit costs as inputs fromtwo different sources, WHO-CHOICE and IHME (see
Additional file 6). The average cost estimates per episode
are much higher when using the IHME unit cost esti-
mates. There may be numerous reasons for these differ-
ences in unit cost estimates including the time when
these data were estimated, as well as the inputs that
went into generating these estimates. However, discuss-
ing the difference between the two sources is beyond the
scope of this paper.
Recognizing the sparseness in empirical data, the mod-
elled estimates in this study were generated to help fill
this data gap. Overall, we find conformity of our mod-
elled cost estimates using the WHO-CHOICE inputs
with the evidence generated from the systematic review.
Our modelled estimates are not meant to precisely rep-
resent costs in any single country, however, in the event
of lack of empirical cost of illness data for specific coun-
tries, our modelled estimates are useful to inform coun-
tries of the value of diarrhea prevention and for
planning purposes.
As with any study, a number of assumptions and limi-
tations should be considered in interpreting these find-
ings. While our literature search was designed to
comprehensively identify recent empirical evidence on
diarrheal disease costs, some articles may have been in-
advertently overlooked. In particular, we excluded stud-
ies from the high-income countries as well as those with
data collection before year 2006. We recognize that
some of those excluded studies may have had represen-
tative, high quality data to contribute to the literature re-
view. Further, we focused our search on general diarrhea
rather than a specific pathogen, but included rotavirus
due to the number of known studies targeting this
pathogen. We recognize this as a potential weakness, but
there is some evidence supporting the hypothesis that
costs may not differ greatly by pathogen once severity
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strated for direct medical costs [51].
We did not formally assess risk of bias of individual
studies and this is a limitation to our analysis. Nonethe-
less, we followed strict guideline for the review, and also
methodologically characterized each study included in
the analysis to obtain harmonized and comparable mea-
sures of primary outcomes. This limits our full under-
standing of the direction of bias.
In addition, we have estimated indirect costs using
GDP per capita as a proxy for the value of caretaker
time. While this is a uniform measure that can be ap-
plied across countries, it has the potential to overstate
indirect costs, particularly in low-income countries
where much of the labor force is in the informal sector
and the GDP per capita may not accurately reflect the
value of productivity costs. Finally, while we view the es-
timates we have generated as useful inputs for planning,
scaling up, and/or evaluating interventions targeting
diarrhea, we also believe that country-specific modelled
estimates should be used cautiously. We would be hesi-
tant to default to modelled estimates when high-quality
empirical estimates are available.Conclusions
Our study sought first to undertake a systematic review
of literature on diarrhea cost of illness in children under
5 years and, second, to generate modelled estimates of
diarrhea cost of illness for children in 137 low-and
middle-income countries. Our modelled estimates gen-
erally correspond to estimates observed in the literature,
with a few exceptions. In the absence of country-specific
estimates, those generated in our model could serve as
useful inputs for planning and prioritizing appropriate
health interventions for childhood diarrheal diseases in
LMICs.Supplementary information
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